In addition to a reduced potential for BRAF inhibitor-activated growth of wild-type RAF cells, the combination of dabrafenib with a MEK inhibitor (trametinib) showed enhanced efficacy in a BRAFV600E tumor xenograft model. Here, MAP2K7 is linked to neoplasm.